SRNE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 15:53):

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases...

Stats
Today's Volume	49 497.00
Average Volume	178 147
Market Cap	6.23M
EPS	$0 ( 2024-05-20 )
Next earnings date	( $0 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.00100 (8.85%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-17	Ji Henry	Buy	19 500	Common Stock
2023-03-17	Ji Henry	Sell	195	Put Option (obligation to buy)
2021-12-31	Janda Kim	Buy	0
2022-12-21	Ji Henry	Buy	300	Common Stock
2022-12-02	Ji Henry	Buy	200	Common Stock

INSIDER POWER
99.97
Last 96 transactions
Buy: 40 331 586 \| Sell: 980 682

Sorrento Therapeutics Inc Correlation

10 Most Positive Correlations
LULU	0.958
CMTL	0.944
EZGO	0.942
SHC	0.937
JWEL	0.936
DCFC	0.934
NDRA	0.933
WOOF	0.931
LPRO	0.931
NEOG	0.929

10 Most Negative Correlations
IVCB	-0.959
KEQU	-0.94
FUSN	-0.939
LABP	-0.936
BCSA	-0.933
SWAV	-0.933
WDC	-0.927
PESI	-0.922
PAYS	-0.922
CDXC	-0.922

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sorrento Therapeutics Inc Financials

Annual	2022
Revenue:	$62.84M
Gross Profit:	$29.39M (46.77 %)
EPS:	$-1.330

FY	2022
Revenue:	$62.84M
Gross Profit:	$29.39M (46.77 %)
EPS:	$-1.330

FY	2021
Revenue:	$52.90M
Gross Profit:	$39.87M (75.37 %)
EPS:	$-1.450

FY	2020
Revenue:	$39.99M
Gross Profit:	$30.05M (75.14 %)
EPS:	$-1.300

Financial Reports:

No articles found.

Sorrento Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.